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Abstract
Although few studies have suggested a carcinogenic role for polymorphism of F31I and V57I codons of AURKA gene in invasive
ductal carcinoma, contradictory results from different populations mandates regional investigations. We aimed to determine
polymorphisms of F31I and V57I codons of AURKA gene and their association with cancer prognosis in patients compared with
controls in an eastern population of Iran.
A case-control study was conducted on specimens from 100 patients and 100 age- and gender-matched controls. DNA was
extracted and the codons F31I and V57I were ampliﬁed. The different genotypes were analyzed by PCR-RFLP and electrophoresis.
In codon F31I, the frequency of Phe/Ile was 70% and 82% in patients and healthy controls respectively, whereas (Ile/Ile) was 30%
in patients and 18% in healthy (P= .047). Analyzing V57I genotypes showed a higher homozygote Val/Val genotype in patients
compared with controls (76% vs 68%), whereas the frequency of heterozygous Val/Ile genotype was lower in patients (17%) than
controls (30%), yielding a marginal association between breast cancer and Val/Val genotype (P= .048). No association was observed
between SNPs of either F31I or V57I genotypes and histological grades. However, there was a signiﬁcant association between tumor
stages and F31I genotype (P for trend= .003).
This is the ﬁrst report of F31I and V57I polymorphisms in AURKA gene in breast cancer in Iran. Determination of allelic
polymorphism of those codons will help to understand background genetic predisposition and could have prognostic value in
management of breast cancer in the target population.
Abbreviations: PCR = polymerase chain reaction, RFLP = restriction fragment length polymorphism analysis.
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Breast cancer is common, with about 1.7 million new cases and
more than 0.5 million deaths in 2012[1]; its incidence is
increasing.[2] The average age at diagnosis is relatively low in
some regions in Iran.[3] Resistance to chemotherapy in breast
cancer may be due to genetic and epigenetic changes in metastatic
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1The aurora kinases regulate important events in the cell cycle.
Aurora A kinase is encoded by the gene AURKA, also known as
STK15 (serine/threonine kinase 15).[5] It regulates the G2 to M
transition into mitosis. Nonsynonymous AURKA polymor-
phisms (91T/A and 169G/A) encode phenylalanine/isoleucine
(F31I) and valine/isoleucine (V57I). These polymorphisms have
been linked with cancers, including breast cancer, identifying
AURKA as a possible oncogene/cancer susceptibility gene.
AURKA is located on chromosome 20 (20q13.2). Its product
is a protein of 403 amino acids with regulatory and catalytic
domains.[6,7] The catalytic domain has a serine/threonine kinase
activity role. AURKA may be ampliﬁed and is overexpressed in
many malignancies including invasive carcinomas of ovary, head
and neck, and breast.[8–10] Overexpression mechanisms and
effects of AURKA in carcinomas are not yet fully understood.
Aurora kinase A controls cell cycle checkpoints and has roles in
centrosome division, cytoskeleton, and cytokinesis. Overexpres-
sion may cause genomic instability via dysregulation of the cell
cycle, leading to tumor development.[11,12] AURKA has been
investigated as a drug target in many animal-model trials.[13,14]
Many studies have suggested that both polymorphisms (F31I
and V57I) are associated with risk of breast cancer.[15–18] Cox
et al found an association between breast carcinoma and F31I
and V57I homozygote alleles in postmenopausal women in the
USA.[16] Similar ﬁndings have been discussed by Ewart-Toland
et al who identiﬁed AURKA as a low-penetrance tumor-
susceptibility gene in mice and humans.[17] Sun et al found that
aurora A kinase Ile/Ile 31 homozygosity was associated with
[18]
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meta-analysis by Dai et al found the isoleucine-encoding AURKA
polymorphism rs2273535T/A (Phe31Ile) increased the risk of
breast cancer in Asians but not Caucasian) while the isoleucine-
encoding rs1047972G/A Val57Ile polymorphism reduced breast
cancer risk in Caucasians but not Asians.[19] There remains a
need for further data on the contribution of AURKA single
nucleotide polymorphisms to breast cancer risk in different
human populations, some of which are very poorly represented in
the published literature.
Furthermore, few studies anywhere have examined the possible
interactions of the SNPs responsible for the F31I and V57I aurora
A kinase polymorphisms with important pathological determi-
nants of breast cancer behavior in different populations. This study
is the ﬁrst attempt to investigate the polymorphisms in SNP of F31I
and V57I codons of AURKA gene in breast cancer in Iranian
patients, including their prognostic value.2. Methods and materials
In this case-control study, 100womenwith breast cancer and 100
healthy controls were compared. The 2 groups were age-matched
with comparable age (mean 47.3±12.8 and 48.1±12.5 years,
respectively).2.1. Histopathological studies
Representative tissue samples were collected from 100 women
diagnosedwith invasive ductal carcinomabetween 2011 and 2015
in themainhospitals of Sabzevar district,North-East Iran. Samples
including tumor tissue were taken for diagnosis and treatment.
The typical surgical specimens were ranged 10 to 25mm in
size. All parts of tumor were cut and blocked sequentially every 2
mm in parafﬁn wax according to our standard practice protocol
of histopathology irrespective of the tumor size. Each block was
then sectioned into 5-mm thick tissues to mount on slides. The 5-
mm sections stained with hematoxylin and eosin were assessed by
2 expert pathologists. The pathologists classiﬁed each carcinoma
using standard criteria for stage and grade. Grade (from 1 to 3)
was based on mitosis counts, nuclear pleomorphism, and acinar
differentiation. The presence or absence of necrosis, maximum
size of the lesion, and surgical margins were also recorded.
Staging employs the standard TNM system.2.2. DNA extraction
DNA was extracted using a standard kit (QIAGEN, Manchester,
UK). Peripheral blood samples were collected from all healthy
controls in 1.5 mL tubes containing 0.5mM EDTA and stored at
20°C or 70°C until required. Stored blood was thawed and
diluted with PBS and cells were separated by Ficoll-Hypaque
gradient centrifugation. Prepared blood samples from healthy
control were used for polymerase chain reaction restriction
fragment length polymorphism analysis (PCR-RFLP). For
patients, 5-mm tumor sections were deparafﬁnized for DNA
extraction. We used spectrophotometer UV and gel electropho-
resis to assess DNA quality.2.3. Polymerase chain reaction restriction fragment length
polymorphism analysis
Codons F31I and V57I of AURKA exon 4 were ampliﬁed, using
lyophilized primers diluted to 5mM dNTP (stoke 10mM) with2deionized sterile water, according to manufacturer’s instructions
(Genet Bio, South Korea). The primer sequences were as follows:
Forward: CTTTCATGAATGCCAGAAAGTT and Reverse:
TCTGCTTCTTCTGATTCTGAACC.[6]
Annealing at 53°C for 60seconds for 38 ampliﬁcation cycles
gave optimal ampliﬁcation (Astech, Japan). Each tube for
polymerase chain reaction (PCR) composed of 2.5mL 10
buffer, 0.8mL of each primer, 5mL of DNA, 0.5mL of dNTP,
2.5mL of magnesium chloride, and DNA polymerase enzyme at
0.2mL which were diluted to the ﬁnal volume of 25mL using
distilled water.
A standard electrophoresis protocol was performed using
1.5% agarose gel, 5mL of each PCR product and 1mL of loading
dye for each, well stained with ethidium bromide (EtBr).
Electrophoresis photographs were taken by gel documentation
machine (Bio-Rad, Hercules, CA).2.4. Restriction fragment length polymorphism analysis
For determination of genotype (polymorphism) of PCR products,
restriction fragment length polymorphism analysis (RFLP) was
performed using 2 different enzymes, ApoI and BstUI.With either
XapI (ApoI) or BstUI at 2mL, a solution composed of Tango 10x
buffer 2mL, nuclease-free water 18mL, and PCR reactionmixture
10mL (Thermo Scientiﬁc, Lithuania) was used. All samples were
incubated at 37°C for 2hours. They were then run on 2.5%
agarose gel and photographs taken after completion.2.5. Statistical analyses
To compare the proportion of cases and controls with a speciﬁc
polymorphism, Chi square and Fisher exact tests were used. The
trend of associations between cancer stages and either F31I or
V57I polymorphisms were tested using cross-tabulations and P
for trend test. For analysis of survival rate, survival distribution
and their associations Kaplan-Meier and log-rank tests were
performed. Differences between cases and controls were taken as
signiﬁcant if P<.05 (2-sided probability). To have an estimate of
sample size in original plan, assuming presence of Phe/Ile
genotype of codon F31I in 85% of controls and 65% of cancer
population, 0.05 type I error and 0.80 type II error, minimum
sample size were 82. Data was analyzed using IBM SPSS package
version 22 (IBM UK, Hampshire, England).2.6. Ethical considerations
The protocol of the study has been reviewed by medical ethics
committee of Sabzevar University of Medical Science and has
been approved under Medsab.IR.REC.1393.16. This study used
project-speciﬁc resources and investigators have rights to share
relevant data after examining the potential collaboration projects
by the relevant research committee.3. Results
3.1. Demographic data
The present study was conducted on 200women: 100 with in situ
or invasive ductal breast carcinoma (mean [±SD] age 47.25±
12.80 years). The healthy control group were age-matched
women (mean [±SD] age of 48.08±12.50 years). The age range
was 25 to 86 years for patients and 23 to 80 years for healthy
controls.
Figure 1. The ﬁgure shows 5m sections from both malignant and healthy tissues. (A) Grade 3 with frequent mitotic and polymorphic brownish color cells. No
nodular differentiation observed. (B) and (C) show grade 2 and 1, respectively, whereas (D) shows healthy cells and tissue (magniﬁcation of all original images:
400).
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3.2.1. Grade. There were 19 (19%) grade 1 carcinomas, 51
(51%) grade 2, and the remaining 30 (30%)were grade 3 (Fig. 1).
3.2.2. Stage. There were 37 cases in disease stage of 0
(carcinoma in situ) or I, of which 11 samples had in situ
carcinoma only, whereas 26 were stage I invasive carcinomas
without lymph nodes involvement.
In 39 cases, lymph nodes or adjacent tissues were involved
(stage II). In 13 cases, the cancer spread to internal mammary
lymph nodes; in some cases even the chest wall was invaded (stage
III). In the remaining cases of invasive ductal carcinoma, 11 cases
were at stage IV (metastatic).3.3. Genotype polymorphism frequencies
3.3.1. Polymorphism of codon F31I. Table 1 shows the
frequencies for heterozygote phenylalanine/isoleucine (Phe/
Ile) and homozygote isoleucine/isoleucine (Ile/Ile). TheTable 1
The frequency of genotype polymorphism of codons F31I and V57I o
Polymorphism Cancer n, %
Codon F31I genotype
Phe/Ile (phenylalanine/isoleucine) 70 (70%)
Ile/Ile (isoleucine/isoleucine) 30 (30%)
Phe/Phe (phenylalanine/phenylalanine) 0
Codon V57I genotype
Val/Val (valine/valine) 76 (76%)
Val/Ile (valine/isoleucine) 17 (17%)
IIe/Ile (isoleucine/isoleucine) 7 (7%)
3frequency of Phe/Ile was 70 (70%) and 82 (82%) in patients
and healthy controls, respectively, whereas (Ile/Ile) was 30
(30%) in patients and 18 (18%) in healthy controls. This
indicates an association between cancer risk and high Ile/Ile/
low Phe/Ile frequencies compared with control (P= .047).
There was no phenylalanine/phenylalanine (Phe/Phe) genotype.
Figure 2 shows examples of ethidium bromide-stained gels
illustrating PCR-RFLP assessment with restriction enzyme
ApoI of the F31I codon with examples of heterozygote Phe/Ile
and homozygote Ile/Ile.
3.3.2. Polymorphism of V57I. There was a higher homozygote
valine/valine (Val/Val) in patients compared with controls (76%
vs 68%), whereas the frequency of heterozygous Val/Ile genotype
was lower in patients (17%) than controls (30%), yielding a
marginal association between breast cancer and high Val/Val
and low Val/Ile genotype, compared to controls (P= .048).
Higher cancer risk in terms of OR (95% CI) was 1.9723f AURKA gene in case and control samples.







Figure 2. PCR-RFLP products lines for F31I codon after adding ApoI enzyme. The PCR product total length was 230bp total length. The length of the cut sections
were 75 and 155bp. Ladder was 50bp for PCR-RLFP. PCR = polymerase chain reaction, PCR-RLFP = polymerase chain reaction restriction fragment length
polymorphism analysis.
Golmohammadi et al. Medicine (2017) 96:37 Medicine(1.0002–3.8893) for high Val/Val and low Val/Ile in cancer
group compared with controls.
The homozygous Ile/Ile genotype was found in 7 (7%) and 2
(2%) of patients and healthy controls, respectively (Table 1).
Association of this genotype with cancer could not be tested
because of small numbers.
Figure 3 shows BstUI digestion products for the V57I codon.
Restriction fragments for heterozygote Val/Ile and homozygote
Val/Val are shown. Figure 4 demonstrates BstUI restriction
fragments of the PCR products for V57I codon showing
heterozygote Val/Ile and noncut homozygote Ile/Ile genotypes.
3.4. Association of tumor grade and stage with
polymorphisms of F31I and V57I
No signiﬁcant associations existed between the F31I or V57I
genotypes and carcinoma grade (Table 2). There was however a
statistically signiﬁcant association between F31I polymorphism
and stage of cancer, indicating lower frequency of Phe/Ile
genotype and higher frequency of Ile/Ile at the more advancedFigure 3. PCR-RFLP products lines for V57I codon after adding BstUI
enzyme. Note the restriction fragments for heterozygote Val/Ile and
homozygote Val/Val. Bands 1 to 7 are PCR products of cancer specimens.
PCR = polymerase chain reaction, PCR-RLFP = polymerase chain reaction
restriction fragment length polymorphism analysis.
4tumor stage (P= .019, P for trend= .003). No signiﬁcant
association between V57I genotype and stage was observed.3.5. Follow up and surviving rate
All cases with invasive ductal carcinoma were followed up for a
minimum of 30 months (Fig. 5). There was no signiﬁcant
association between survival and any speciﬁc genotype in codon
V57I. However, mean survival was worse for patients who were
homozygote for Ile/Ile in codon F31I compared with other
genotypes [20.9 (95% CI: 14.1–27.7)].
4. Discussion
Genetic and epigenetic factors inﬂuencing breast cancer risk
include polymorphisms involving genes, including AURKA.
Allele frequencies vary in different human populations. Despite
wide investigation, the contribution of AURKA V57I and F31I
polymorphisms to breast cancer risk is still controversial:Figure 4. PCR-RFLP products lines for V57I codon after adding BstUI
enzyme. Note the length of cuts after digestion for heterozygote Val/Ile, and
noncut homozygote Ile/Ile. The PCR product total length was 230bp. The
length of the cut sections were 65 and 165bp. PCR = polymerase chain
reaction, PCR-RLFP = polymerase chain reaction restriction fragment length
polymorphism analysis.
Table 2
Histological characteristics of breast cancer associated with polymorphisms of F31I and V57I in AURKA gene.
Characteristics
F31I V57I
Phe/Ile n, % Ile/Ile n, % Val/Val n, % Val/Ile n, % Ile/Ile n, %
Stage of cancer
0/I 30 (43%) 7 (23%) 29 (38%) 6 (35%) 2 (29%)
II 28 (40%) 11 (37%) 30 (39%) 7 (41%) 2 (29%)
III 9 (13%) 4 (13%) 10 (13%) 2 (12%) 1 (14%)
IV 3 (4%) 8 (27%) 7 (9%) 2 (12%) 2 (29%)
Statistical signiﬁcance X2P value= .019; P for trend= .003 NS
Grade of tumor
1 12 (17%) 7 (23%) 16 (21%) 3 (18%) 0 (0%)
2 40 (57%) 11 (37%) 42 (55%) 7 (41%) 2 (29%)
3 18 (26%) 12 (40%) 18 (24%) 7 (41%) 5 (71%)
Statistical signiﬁcance NS NS
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AURKA V57I or F31I and breast cancer remains elusive.
AURKA helps to maintain chromosome integrity after DNA
damage.[20] A role for nonsynonymous AURKA polymorphisms
in carcinogenesis is at least mechanistically plausible.[21,22]
Nikonova et al showed association of overexpression of AURKA
with defective mitotic spindles, supernumerary centrosomes,
chromosomal instability, aneuploidy, and apoptosis resistance.[5]
In Finland, Staff et al reported AURKA overexpression in 21%
of 126 patients with breast cancer.[15] Overexpression of AURKA
is associated with autophagy inhibition[23] and Taxol resistance
in breast cancer.[24] Studies in Chinese Han population showed
associations between AURKA polymorphisms and breast cancer
risk; the association was stronger when another polymorphism in
BRCA1 was present.[22]
A meta-analysis of 14 case-control studies of cancer suscepti-
bility comprising 11,245 cases, and 16,024 controls suggested a
protective effect of AURKA V57I polymorphism, especially in
Caucasians, rather than Asians; analysis by ethnicity indicated a
decreased risk of breast cancer in Caucasians speciﬁcally.
However, even the large sample size did not provide enough
statistical power for deﬁnitive conclusions.[25]Figure 5. Association between patients’ survival and single nucleotide in codon V
V57I had signiﬁcantly worst survival rate.
5King et al claimed a role in mammary carcinogenesis for the
F31I polymorphism, but not for V57I.[26] Qin et al showed that
the F31I Ile/Ile allele predisposes Asians and Caucasians women
to breast cancer, but found no signiﬁcant association between the
V57I polymorphism and breast cancer risk.[27] In contrast,
Fletcher et al found no consistent association between breast
cancer risk and the F31I polymorphism inwhite women of British
descent. However, their results may reﬂect the potential
geographic-dependent genetics risk factors in the UK. Addition-
ally, statistically signiﬁcant heterogeneity in odds ratio estimates
may reﬂect population-speciﬁc linkage disequilibrium with a
functional variant or artifacts, including population stratiﬁcation
or publication bias.[28]
These conﬂicting ﬁndings suggest that other factors may
modify associations between F31I and V57I AURKA polymor-
phisms and breast cancer, which could be regional dependent. In
interpretation of results, we should acknowledge that these
studies in different regions had different sample size and method
of analysis, and did not include all life-style and environmental
factors, including diet, physical activities, and various exposure
to hormone replacement therapy. If there is any consensus, it is
that the F31I polymorphism does modify breast cancer risk. Tang57I (left) or codon F31I (right). Note only patients with Ile/Ile genotype in codon
[3] Golmohammadi R, Pejhan A . The prognostic value of the P53 protein
Golmohammadi et al. Medicine (2017) 96:37 Medicineet al in their meta-analysis study of 19,267 cancer cases and
24,359 controls supported this conclusion concerning the F31I
polymorphism and breast cancer.[29]
The main goal of our study was to examine association (if any)
between the cancer risk and polymorphisms of AURKA F31I and
V57I codons in the North-East Iran. Our results were in
agreement with most of aforementioned studies and showed a
higher frequency for homozygous Ile/Ile genotypes at the F31I
locus in patients with breast cancer compared to healthy controls
in North-East Iran. To the best of our knowledge, it is the ﬁrst
report to ﬁnd an association between F31I Ile/Ile homozygosity
and breast cancer in the Middle East. It is possible that the higher
incidence of invasive ductal carcinoma in this area could be linked
to a higher frequency of the Ile coding allele at F31I genotype. We
also observed a signiﬁcant association between the Ile/Ile F31I
genotype and higher stage of breast carcinoma in our patients.
Ruan et al reported an association between homozygote (Ile/Ile)
genotype of F31I codon (rs2273535) and signiﬁcant increased
risk of breast cancer among the Chinese Han population.[22] Dai
et al showed elevated risk of breast cancer in association with
Phe/Ile and Ile/Ile genotypes at codon 31 of the AURKA gene.[30]
They also found an association between breast cancer risk,
obesity, and Ile/Ile homozygosity. In another study in which
Caucasians were recruited Dai and colleagues reported the same
link between F31I polymorphism and risk of breast cancer, but
not for V57I.[19]
To explore the mechanism of the AURKA gene mutations in
the development and progression of the breast cancer, a new
study suggested that AURKA protein kinase is involved in
vasculogenic mimicry of cancer stem cells and may become a new
treatment target in suppressing vasculogenic mimicry and
metastasis of breast cancer.[31]
Our study also showed that patients with the shortest survival
hadmore homozygote Ile/Ile in codon F31I and had higher tumor
stages compared with other cases, supporting an association
between breast cancer and homozygote Ile/Ile genotypes at
AURKA codon 31.[21] Of course, many other factors inﬂuence
breast carcinogenesis, including hormone receptors and TP53
with its important role in apoptosis.
Further studies with larger sample size and longer follow-up
can be justiﬁed to let us address outstanding controversies in this
area. Breast cancer risk stratiﬁcation is important for earlier
detection and more effective treatment. Economic and cultural
obstacles to effective breast cancer management also need to be
addressed.Acknowledgments
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